This company has been marked as potentially delisted and may not be actively trading. Third Harmonic Bio (THRD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock THRD vs. AVXL, PRAX, SYRE, UPB, TRVI, SION, GERN, MLYS, URGN, and IMNMShould you be buying Third Harmonic Bio stock or one of its competitors? The main competitors of Third Harmonic Bio include Anavex Life Sciences (AVXL), Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE), Upstream Bio (UPB), Trevi Therapeutics (TRVI), Sionna Therapeutics (SION), Geron (GERN), Mineralys Therapeutics (MLYS), Urogen Pharma (URGN), and Immunome (IMNM). These companies are all part of the "med - biomed/gene" industry. Third Harmonic Bio vs. Its Competitors Anavex Life Sciences Praxis Precision Medicines Spyre Therapeutics Upstream Bio Trevi Therapeutics Sionna Therapeutics Geron Mineralys Therapeutics Urogen Pharma Immunome Third Harmonic Bio (NASDAQ:THRD) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Does the media favor THRD or AVXL? In the previous week, Anavex Life Sciences had 15 more articles in the media than Third Harmonic Bio. MarketBeat recorded 16 mentions for Anavex Life Sciences and 1 mentions for Third Harmonic Bio. Anavex Life Sciences' average media sentiment score of 0.29 beat Third Harmonic Bio's score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Third Harmonic Bio Neutral Anavex Life Sciences Neutral Which has more risk and volatility, THRD or AVXL? Third Harmonic Bio has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Do analysts rate THRD or AVXL? Third Harmonic Bio currently has a consensus target price of $5.00, indicating a potential downside of 7.06%. Anavex Life Sciences has a consensus target price of $44.00, indicating a potential upside of 342.66%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Third Harmonic Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Third Harmonic Bio 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is THRD or AVXL more profitable? Third Harmonic Bio's return on equity of -19.27% beat Anavex Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Third Harmonic BioN/A -19.27% -18.67% Anavex Life Sciences N/A -45.67%-40.21% Do institutionals & insiders hold more shares of THRD or AVXL? 94.0% of Third Harmonic Bio shares are owned by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are owned by institutional investors. 7.8% of Third Harmonic Bio shares are owned by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, THRD or AVXL? Anavex Life Sciences is trading at a lower price-to-earnings ratio than Third Harmonic Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioThird Harmonic BioN/AN/A-$45.47M-$0.62-8.68Anavex Life SciencesN/AN/A-$43M-$0.57-17.44 SummaryAnavex Life Sciences beats Third Harmonic Bio on 8 of the 13 factors compared between the two stocks. Get Third Harmonic Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THRD vs. The Competition Export to ExcelMetricThird Harmonic BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$242.80M$3.09B$5.66B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-4.3720.3830.5825.12Price / SalesN/A356.76462.42114.82Price / CashN/A42.3037.4059.05Price / Book0.858.659.096.18Net Income-$45.47M-$54.65M$3.25B$264.89M Third Harmonic Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THRDThird Harmonic Bio0.3103 of 5 stars$5.38flat$5.00-7.1%N/A$242.80MN/A-4.37N/AAVXLAnavex Life Sciences3.8289 of 5 stars$10.78-5.0%$44.00+308.2%+57.5%$969.48MN/A-19.6040Earnings ReportAnalyst ForecastPRAXPraxis Precision Medicines1.8615 of 5 stars$48.46+7.8%$95.22+96.5%-13.6%$946.01M$8.55M-3.94110SYRESpyre Therapeutics3.1311 of 5 stars$15.89+4.2%$53.40+236.1%-36.2%$921.11M$890K-4.6773Positive NewsUPBUpstream Bio1.8826 of 5 stars$17.50+5.5%$56.50+222.9%N/A$894.36M$2.37M0.0038TRVITrevi Therapeutics3.0669 of 5 stars$7.33+0.1%$20.38+178.0%+173.5%$892.02MN/A-17.4520Analyst RevisionSIONSionna Therapeutics2.1217 of 5 stars$20.99+4.8%$38.50+83.4%N/A$883.81MN/A0.0035Positive NewsEarnings ReportAnalyst UpgradeGap UpHigh Trading VolumeGERNGeron3.3542 of 5 stars$1.35-0.7%$4.19+210.2%-67.5%$867.70M$76.99M-10.38229Analyst RevisionMLYSMineralys Therapeutics3.2181 of 5 stars$13.51+2.4%$32.25+138.7%+48.8%$859.66MN/A-3.6228News CoverageEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionURGNUrogen Pharma4.6226 of 5 stars$19.20+5.3%$31.43+63.7%+27.2%$843.86M$90.40M-5.78200Insider TradeAnalyst RevisionIMNMImmunome1.8243 of 5 stars$9.91+2.6%$23.14+133.5%-26.3%$840.85M$9.04M-3.2240 Related Companies and Tools Related Companies Anavex Life Sciences Competitors Praxis Precision Medicines Competitors Spyre Therapeutics Competitors Upstream Bio Competitors Trevi Therapeutics Competitors Sionna Therapeutics Competitors Geron Competitors Mineralys Therapeutics Competitors Urogen Pharma Competitors Immunome Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THRD) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Third Harmonic Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Third Harmonic Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access